2023 Autumn Conference – Includes Joint Day with ECNP
ECNP/ISCTM Joint Meeting Prior to 36th ECNP Congress 2023: CNS Clinical Trial Methodology
05 – 07 October, 2023 // Barcelona, Spain
Distinguished Poster Award Recipient:
|
|||
| Psilocybin therapy for treatment resistant depression: Prediction of clinical outcome by natural language processing (Dougherty; Abstract) | |||
|
View all Poster PDFs and Abstracts |
|||
6 October 2023 |
|||
| Welcome from the ISCTM and ECNP Presidents | Martien Kas Gary Sachs  slides video |
||
| Session 1: Novel quantitative analysis method to address placebo effects in CNS trials | Chairs: Danièle Laverdure-Dupont Eduard Vieta |
||
| Introduction: Perspectives on the placebo effect – from academia to pharma | Danièle Laverdure-Dupont slides video |
||
| Psychological and neurobiological mechanisms underlying placebo responses and their clinical consequences | Fabrizio Benedetti video*
|
||
| Placebo prognostic covariates: Use of unique patient characteristics to leverage the full potential of prognostic covariates and their implementation in RCTs | Dominique Demolle slides video |
||
| Biostatistical considerations around the use of traditional or AI-based covariates in registrational trials | Anzalee Khan slides video |
||
| Predicting placebo responsiveness using machine learning and explainable AI | Manuel Montoya slides video |
||
| Regulatory acceptability of placebo responsiveness prediction tools in registrational trials | Khadija Rantell slides video Dawn Velligan slides video |
||
| Panel discussion | Facilitator: Eduard Vieta slides video |
||
|
Session 2: Prescription digital therapeutics (PDTs) for CNS disorders |
Chairs: Shaheen Lakhan Gerard Dawson |
||
| A primer on digital therapeutics | Shaheen Lakhan slides video |
||
| Bringing digital therapeutics to the psychiatric patient population | Gerard Dawson slides video |
||
| What are appropriate control conditions for prescription digital therapeutics (PDTs)? | Jacqueline Lutz slides video |
||
| Developing neuromodulation interventions for mental health digital therapeutics | Brian Iacoviello slides video |
||
| Regulating PDTs: The German experience | Jonas Albert slides video |
||
| Digital therapeutic regulation pathways in the USA | Megan Coder slides video |
||
| Prescription digital therapeutics: Optimizing third party coverage, operationalizing access | Paul Jeffrey slides video |
||
| European taskforce for harmonized evaluation of digital medicine devices (DMDs) | Fruzsina Mezei slides video |
||
| Panel discussion | video |
||
|
Poster Session |
Poster PDFs and Abstracts | ||
7 October 2023 |
|||
| Session 3: Are our clinician rated psychopathology measures fit for purpose decades later? | Chairs: Nina Schooler Celso Arango Stephen Marder |
||
| Introduction: Setting the problem into perspective | Nina Schooler slides video |
||
| Schizophrenia and psychosis: What are identified deficiencies of our current psychopathology rating scales? | Celso Arango slides video |
||
| Major depression: Are we asking the right questions? | Koen Demyttenaere video* |
||
| Bipolar disorder: What are identified deficiencies of our current psychopathology rating scales for exemplar diagnoses? | Eduard Vieta slides video (includes discussion with Arango and Demyttenaere) |
||
| Strategies for developing new and improved consensus instruments | Stephen Marder slides video |
||
| Linking established clinical items to objective/passive measurements: In search of an elusive “gold standard” | Vikas Mohan Sharma slides video |
||
| Using large banks of items and computer adaptive testing to improve clinical outcome assessment | Nina Schooler slides video |
||
| Measurement resolution is the key to advancing digital phenotyping beyond “proof of concept” | Alex Cohen slides video |
||
| Speaker and Stakeholder panel discussion | Panelist: Silvia Zaragoza Domingo All Speakers video |
||
| Session adjourns | Gary Sachs slides video |
||
|
Concurrent Working Group Sessions |
|||
| Accelerating development of psychopathology measures – ISCTM/ECNP joint working group | Chairs: Nina Schooler Celso Arango Jenicka Engler slides |
||
| Methodological issues in study designs for clinical trials with psychedelics working group | Chairs: Amir Inamdar Joyce Tsai slides |
||
| Orphan diseases working group | Chairs: Joan Busner Gahan Pandina slides |
||
| *Slides not released | |||